Products & Pipeline

KalVista is advancing a pipeline of novel, small molecule plasma kallikrein inhibitors through preclinical and clinical development. We intend to develop these drug candidates as potential best-in-class treatments for hereditary angioedema (HAE), diabetic macular edema (DME), and other plasma kallikrein-associated diseases.

Our development programs have received grant funding from the JDRF, Innovate UK and the European Commission.